Oura Health, the $2.55 billion Finnish health wearables maker, has accelerated its public listing timeline after internal revenue data showed enterprise contract sales outperforming management's own forecasts. The company confirmed to institutional backers that B2B revenue now represents a larger growth vector than direct-to-consumer hardware sales, a reversal of the founder thesis established during Series C negotiations in 2021.
The company disclosed during pre-roadshow diligence that commercial partnerships with employers, health systems, and insurance carriers generated $147 million in trailing twelve-month revenue as of Q4 2024, representing 41% of total topline and growing at 183% year-over-year. Consumer hardware sales, including the third-generation ring launched in October 2023, grew 34% over the same period. Founding CEO Harpreet Rai told institutional allocators the enterprise pipeline includes 22 Fortune 500 names under active contract negotiation, with average contract values between $2.8 million and $6.1 million annually. The company manufactures its titanium sensor rings in Finland and Vietnam, with gross margins on enterprise contracts running 68% versus 52% on direct consumer sales.
This matters because hardware-to-SaaS margin expansion is the single narrative institutional buyers demand from wearables companies attempting public listings after Fitbit's disappointing exit to Google in 2021 and Whoop's stalled IPO process. Oura's enterprise revenue mix provides a defensible moat: corporate wellness budgets are stickier than consumer discretionary spend, and the company retains pricing power through annual subscription fees tied to biometric data access. The average enterprise customer maintains 89% device utilization rates across employee populations, compared to 63% engagement among direct consumers after twelve months. Allocators evaluating the filing will focus on churn rates inside corporate contracts and whether the $5.99 monthly membership fee can sustain pricing in a market where Apple and Samsung offer comparable metrics without subscription models. Oura's defense is data fidelity: the ring captures continuous temperature, heart rate variability, and sleep architecture with clinical-grade precision that wrist-worn devices cannot match, a claim validated in 14 peer-reviewed studies published since 2022.
The S-1 filing timing aligns with a narrow window before Federal Reserve policy uncertainty closes institutional appetite for growth-stage hardware IPOs. Bankers at Goldman Sachs and Morgan Stanley, the expected joint bookrunners, are advising Oura to target a March 2025 roadshow with pricing in early April, assuming no macro disruption. The company will need to demonstrate that enterprise revenue isn't front-loaded through one-time device deployments but instead generates recurring data service fees that compound. Management's guidance suggests $480 million in total 2025 revenue with enterprise contracts contributing $215 million, implying the commercial segment must sustain triple-digit growth while consumer hardware matures into mid-twenties percentage gains. Institutional allocators should track whether Oura can sign three additional top-tier health systems before filing, a threshold that would validate the enterprise thesis and support a 14x-16x revenue multiple at debut.
The filing will surface whether venture backers including The Chernin Group, Forerunner Ventures, and Dexcom are planning secondary liquidity or remain locked through a standard 180-day quiet period. The company raised $200 million in Series D at a $2.55 billion post-money valuation in November 2024, leaving early investors with unrealized gains exceeding 18x on sub-2019 entry prices. If enterprise revenue holds momentum through Q1 2025 earnings, Oura becomes the first consumer health hardware company to cross into public markets with a validated B2B model, resetting allocator expectations for the sector.